Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Email address * A link to set a new password will be sent to your email address
Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity Marie Bosslett, Assistant Editor Yasmeen Qahwash Key Takeaways The TOGETHER-PsA trial showed that combining ixekizumab and tirzepatide improves PsA outcomes in patients with obesity, surpassing ixekizumab monotherapy
For uninsured or underinsured patients, compounded options may enable access to semaglutide therapy that branded pricing prohibits
Mazdutide Availability Mazdutide has not yet received approval from Health Canada
N Engl J Med 2021;385:50315.ArticlePubMed 91
US$ 20.98
US$ 25.71
US$ 29.28
